ArticleFEBS open bio2020
TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma.
Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.Signal transduction and targeted therapy · 2024Trial
- Role of glycolysis related genes in the pathogenesis of hemorrhoids and immune cell infiltration analysis.Scientific reports · 2025Article
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- Diagnostic value of procalcitonin and hemocyte parameters in neonates with bloodstream infection: Role of activated hemocyte-related genes.Pediatric discovery · 2024Article
- Bioinformatic Approaches for the Identification of Novel Tumor Suppressor Genes and Cancer Pathways in Renal Clear Cell Carcinoma.Iranian journal of biotechnology · 2024Article
- Article
- FAM72 family proteins as poor prognostic markers in clear cell renal carcinoma.Biochemistry and biophysics reports · 2023Article
- Bioinformatics-based identification of lipid- and immune-related biomarkers in abdominal aortic aneurysms.Heliyon · 2023Article
- Identification of Differentially Methylated Genes Associated with Clear Cell Renal Cell Carcinoma and Their Prognostic Values.Journal of environmental and public health · 2023Article
- Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network.Biochemical genetics · 2022Article
- Gene co-expression analyses of health(span) across multiple species.NAR genomics and bioinformatics · 2022Article
- The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration.BMC cancer · 2022Article
- Single-cell RNA Sequencing Analysis Reveals New Immune Disorder Complexities in Hypersplenism.Frontiers in immunology · 2022Article
- Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer.Frontiers in endocrinology · 2022Article
- Identification of TYROBP and FCER1G as Key Genes with Prognostic Value in Clear Cell Renal Cell Carcinoma by Bioinformatics Analysis.Biochemical genetics · 2021Article
- Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.BMC cancer · 2021Article
- Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art.Current urology reports · 2021Review
- Classification of Osteosarcoma Based on Immunogenomic Profiling.Frontiers in cell and developmental biology · 2021Article
- A Tumor Progression Related 7-Gene Signature Indicates Prognosis and Tumor Immune Characteristics of Gastric Cancer.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) exhibits high recurrence and metastasis rates. Although target therapy has significantly improved the prognosis of some patients with ccRCC, the median survival rate remains poor. Thus, there remains a need for the identification of novel potential targets for diagnosis and therapy. Here, we screened differentially expressed genes between ccRCC and normal tissues through analyzing The Cancer Genome Atlas database. We identified 55 up-regulated and 67 down-regulated genes associated with poor prognosis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that these genes were associated with glycometabolic process, complement and coagulation cascades. In addition, the eight down-regulated genes (HRG, FABP1, ALDOB, PCK1, HAO2, CASR, PLG, and HMGCS2) and two up-regulated genes (SERPINE1 and TYROBP) were filtered out. Finally, TYROBP was selected through repeated verification of various databases. High expression of TYROBP is associated with low survival rate in ccRCC, is closely related to immune cell infiltration and is coexpressed with Programmed cell death protein-1(PD-1) and Cytotoxic T lymphocyte-associated antigen-4(CTLA-4). In conclusion, TYROBP may have potential for diagnosis and treatment of ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.